YS Biopharma Co (YS Biopharma Co) Debt-to-EBITDA : -1.97 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is YS Biopharma Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

YS Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $25.73 Mil. YS Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $50.21 Mil. YS Biopharma Co's annualized EBITDA for the quarter that ended in Sep. 2023 was $-38.50 Mil. YS Biopharma Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -1.97.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for YS Biopharma Co's Debt-to-EBITDA or its related term are showing as below:

YS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.49 Med: -5.66 Max: -0.16
Current: -2.26

During the past 3 years, the highest Debt-to-EBITDA Ratio of YS Biopharma Co was -0.16. The lowest was -6.49. And the median was -5.66.

YS's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.36 vs YS: -2.26

YS Biopharma Co Debt-to-EBITDA Historical Data

The historical data trend for YS Biopharma Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YS Biopharma Co Debt-to-EBITDA Chart

YS Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-EBITDA

-0.16

-5.66

-6.49

YS Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial			-	-4.42	10.54	-2.53	-1.97

Competitive Comparison of YS Biopharma Co's Debt-to-EBITDA

For the Biotechnology subindustry, YS Biopharma Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

YS Biopharma Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, YS Biopharma Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where YS Biopharma Co's Debt-to-EBITDA falls into.

YS Biopharma Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

YS Biopharma Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(28.805	+	43.556)	/	-11.145
	=	-6.49

YS Biopharma Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(25.729	+	50.21)	/	-38.5
	=	-1.97

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

YS Biopharma Co (NAS:YS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

YS Biopharma Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of YS Biopharma Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

YS Biopharma Co (YS Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » YS Biopharma Co Ltd (NAS:YS) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.